Keratitis
3
Pipeline Programs
4
Companies
4
Clinical Trials
0
Approved Products
Pipeline by Development Stage
Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
0
1
2
Early DiscoveryClinical DevelopmentMarket
Competitive Landscape
4 companies ranked by most advanced pipeline stage
Bausch + LombNJ - Bridgewater
1 programSafety of Overnight Corneal Reshaping LensesN/A1 trial
Active Trials
Trial Timeline
Clinical trial activity over time
2021
2022
2023
2024
2025
2026
Santen1mg/mL ciclosporin
AlconB+L Biotrue MPS and B+L PureVision
Thea PharmaT4020
Bausch + LombSafety of Overnight Corneal Reshaping Lenses
Clinical Trials (4)
Total enrollment: 1,334 patients across 4 trials
Effect of IKERVIS® Eye Drops Once Daily on the Quality of Vision in Dry Eye Disease Patients With Severe Keratitis
Start: Mar 2017Est. completion: Jul 201817 patients
Phase 4Completed
Study of the Presence and Extent of Corneal Disturbance Associated With B+L Biotrue MPS Used With B+L PureVision Lenses
Start: Oct 2010Est. completion: Dec 2010
Phase 4Completed
Efficacy and Safety Assessment of T4020 Versus Vehicule in Patients With Chronic Neurotrophic Keratitis or Corneal Ulcer
Start: Feb 2013Est. completion: Dec 2017
Phase 3Completed
Safety of Overnight Corneal Reshaping Lenses
Start: Feb 2008Est. completion: Oct 20101,317 patients
N/ACompleted
Phase Legend
Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available
Key Insights
1 late-stage (Phase 3) programs — potential near-term approvals
4 companies competing in this space